AGTC Announces Completion of Enrollment in All Adult Dose Groups of Its Ongoing Phase 1/2 Clinical Trials in Patients With Achromatopsia (Globe Newswire)

AGTC Announces Completion of Enrollment in All Adult Dose Groups of Its Ongoing Phase 1/2 Clinical Trials in Patients With Achromatopsia

UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its Phase 1/2 clinical programs with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. The company continues to enroll pediatric patients at the higher dose groups in both trials.

“We expect the information to be obtained from these adult dose groups, as well as the additional pediatric data, will help to reinforce the encouraging preliminary data generated to date and previously reported in September 2019 and January 2020,” said Sue Washer, president and CEO of AGTC.

Learn more about AGTC Announces Completion of Enrollment in All Adult Dose Groups of Its Ongoing Phase 1/2 Clinical Trials in Patients With Achromatopsia.
X